Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global leader in drug delivery platforms, has revealed promising results from its 8-week animal study, WEIGHT-A24-1. The study is uniquely focused on evaluating the performance of liraglutide processed with Lexaria's patented DehydraTECH technology.
The results indicate that DehydraTECH-liraglutide is outperforming DehydraTECH-semaglutide. This outcome is particularly noteworthy as semaglutide has been shown in other human studies to be more than twice as effective at promoting weight loss compared to liraglutide. The continued superior performance of DehydraTECH-liraglutide thus holds significant potential implications for diabetes and weight management treatments.
Furthermore, the study results also show that certain DehydraTECH-CBD formulations are outperforming DehydraTECH-semaglutide, adding another layer of interest to the ongoing research. The study is still in progress, with additional results expected in the coming weeks.
DehydraTECH is Lexaria's patented drug delivery system designed to enhance the bio-absorption of active pharmaceutical ingredients (APIs) when administered orally. Since its inception in 2016, the technology has been applied to a variety of beneficial molecules in both oral and topical formats, consistently demonstrating increased bio-absorption and improved delivery across the blood-brain barrier.
Lexaria's innovative approach could lead to more effective treatments for diabetes and obesity, potentially improving the quality of life for millions of people worldwide. The ongoing success of the DehydraTECH technology in these studies could also pave the way for its application to other centrally active compounds, further broadening its impact on the pharmaceutical industry.
